Viridian Therapeutics (VRDN) Competitors $18.87 -0.78 (-3.97%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$18.87 0.00 (0.00%) As of 09/12/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN vs. RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, PRVA, VCYT, and HTFLShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), Veracyte (VCYT), and Heartflow (HTFL). These companies are all part of the "healthcare" industry. Viridian Therapeutics vs. Its Competitors RadNet Option Care Health Sotera Health BrightSpring Health Services GeneDx Concentra Group Holdings Parent Surgery Partners Privia Health Group Veracyte Heartflow RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership. Is RDNT or VRDN more profitable? RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RadNet-0.78% 2.41% 0.82% Viridian Therapeutics -112,806.88%-78.95%-49.91% Which has stronger valuation and earnings, RDNT or VRDN? RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRadNet$1.83B3.11$2.79M-$0.20-370.05Viridian Therapeutics$300K5,137.04-$269.95M-$3.83-4.93 Does the media prefer RDNT or VRDN? In the previous week, RadNet had 5 more articles in the media than Viridian Therapeutics. MarketBeat recorded 14 mentions for RadNet and 9 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.54 beat RadNet's score of 1.13 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility and risk, RDNT or VRDN? RadNet has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Do analysts prefer RDNT or VRDN? RadNet presently has a consensus price target of $76.80, indicating a potential upside of 3.77%. Viridian Therapeutics has a consensus price target of $37.78, indicating a potential upside of 100.20%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than RadNet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RadNet 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.25Viridian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Do insiders and institutionals have more ownership in RDNT or VRDN? 77.9% of RadNet shares are owned by institutional investors. 5.6% of RadNet shares are owned by insiders. Comparatively, 1.6% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryRadNet beats Viridian Therapeutics on 12 of the 17 factors compared between the two stocks. Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.60B$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-4.9321.1774.5225.93Price / Sales5,137.04476.06548.33126.97Price / CashN/A46.6837.5660.44Price / Book3.109.6112.166.29Net Income-$269.95M-$53.29M$3.28B$270.77M7 Day Performance0.80%0.28%0.87%3.88%1 Month Performance0.11%5.73%4.96%4.88%1 Year Performance-14.46%10.52%60.74%26.01% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics2.2362 of 5 stars$18.87-4.0%$37.78+100.2%-8.8%$1.60B$300K-4.9350Positive NewsRDNTRadNet3.4388 of 5 stars$71.99+0.8%$76.80+6.7%+10.1%$5.49B$1.83B-359.9311,021Positive NewsInsider TradeOPCHOption Care Health4.8732 of 5 stars$29.59+1.7%$35.75+20.8%-10.4%$4.72B$5.00B23.678,088Positive NewsSHCSotera Health2.1687 of 5 stars$15.91+1.9%$16.00+0.6%-2.6%$4.44B$1.10B198.903,000Positive NewsInsider TradeHigh Trading VolumeBTSGBrightSpring Health Services2.4603 of 5 stars$25.48+5.6%$25.67+0.7%+88.4%$4.27B$11.27B82.2035,000News CoverageAnalyst ForecastHigh Trading VolumeWGSGeneDx2.5735 of 5 stars$129.33-2.4%$101.63-21.4%+224.7%$3.81B$305.45M2,586.601,200Positive NewsAnalyst ForecastCONConcentra Group Holdings Parent3.0477 of 5 stars$22.79-1.3%$27.50+20.7%-1.7%$2.96B$1.90B19.1511,250Positive NewsSGRYSurgery Partners3.1614 of 5 stars$22.08-1.9%$33.00+49.5%-27.0%$2.89B$3.11B-15.4415,000Positive NewsPRVAPrivia Health Group4.5296 of 5 stars$23.59+1.3%$28.58+21.2%+21.0%$2.86B$1.74B214.471,140Positive NewsVCYTVeracyte3.8465 of 5 stars$32.46+0.1%$40.90+26.0%+1.5%$2.55B$445.76M98.37790Positive NewsHTFLHeartflowN/A$34.50+11.0%$35.80+3.8%N/A$2.52BN/A0.00699Quiet Period Expiration Related Companies and Tools Related Companies RDNT Competitors OPCH Competitors SHC Competitors BTSG Competitors WGS Competitors CON Competitors SGRY Competitors PRVA Competitors VCYT Competitors HTFL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRDN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRDN Stock Alerts